Krystal Biotech, Inc. KRYS
Updated: 8 Sep 2026
No signal published yet
We already track Krystal Biotech and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Krystal Biotech, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Krystal Biotech free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 3, 2026, Krystal Biotech announced its second-quarter 2026 financial results, generating $119.2 million in global net revenue from Vyjuvek. This represents a 24% increase year-over-year and yielded a quarterly net income of $54.8 million. The company also confirmed ongoing preparations to launch Vyjuvek in Spain and Italy later in the year.
What Firelda Watch includes for Krystal Biotech, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Krystal Biotech, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Krystal Biotech free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more